Johnson & Johnson

EU regulators review Janssen’s esketamine nasal spray antidepressant

https://pharmaphorum.com/news/eu-regulators-review-janssens-esketamine-nasal-spray-antidepressant/

Pharma depriving developing countries of taxes – report

https://pharmaphorum.com/news/pharma-depriving-developing-countries-of-taxes-report/

https://pharmaphorum.com/news/jj-trumpets-new-data-from-tremfya-as-psoriasis-market-braces-for-biosimilars/

J&J files esketamine nasal spray antidepressant in US

https://pharmaphorum.com/news/jj-files-esketamine-nasal-spray-antidepressant-in-us/

Celltrion hopes to outdo inflammatory disease rivals with SC infliximab

https://pharmaphorum.com/news/celltrion-hopes-to-outdo-inflammatory-disease-rivals-with-sc-infliximab/

Johnson & Johnson leads the way to a world without disease

https://pharmaphorum.com/views-analysis-digital/world-without-disease-johnson-johnson-leads/

J&J hopes to overturn $4.69bn compensation bill

https://pharmaphorum.com/news/jj-hopes-to-overturn-4-69bn-compensation-bill/

J&J’s Tremfya gets funding in Germany and UK

https://pharmaphorum.com/news/jjs-tremfya-funding-germany-uk/

FDA approves Pfizer’s epoetin biosimilar Retacrit

https://pharmaphorum.com/news/fda-approved-pfizers-epoetin-biosimilar-retacrit/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search